Compare
Gilead Sciences vs Repligen (GILD vs RGEN)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Gilead Sciences (GILD) returned +36.1% and Repligen (RGEN) +19.0%; so far this year the figures are +36.0% and +5.9%.
Gilead Sciences is the larger company by market value, about 18.7 times the size of Repligen.
Revenue grew +6.5% at GILD and +13.8% at RGEN over the last year.
GILD yields 1.95%. RGEN pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| GILD | RGEN | |
|---|---|---|
| Price | $166.89 | $173.49 |
| 1-day | -0.41% | +2.97% |
| YTD | +35.97% | +5.88% |
| 1 year | +36.15% | +18.96% |
| 3 years | +108.12% | +31.97% |
| Market cap | $207.0B | $11.1B |
| P/E | — | — |
| P/S | 6.68 | 13.77 |
| P/B | 15.87 | 5.30 |
| Revenue growth | +6.50% | +13.80% |
| EPS growth | -149.00% | -2200.00% |
| Gross margin % | 79.9 | 53.5 |
| Net margin % | -12.5 | -1.5 |
| ROE % | -29.6 | -0.6 |
| Debt / equity | 2.01 | 0.27 |
| FCF yield % | 6.7 | 1.0 |
| Dividend yield % | 1.95 | — |
| Beta | 0.37 | 1.24 |
| RSI (14) | 60.2 | 47.0 |
| Technical rating |